
    
      The study will include a Screening Visit, a Prospective Outpatient Baseline Period (2 to 3
      weeks), an Inpatient Period (3 weeks), an Outpatient Period (8 weeks of treatment and 2 weeks
      of taper), and a Safety Follow-Up Period (4 weeks). The total study duration after screening
      will be 19 to 20 weeks. Approximately 6 months after the last visit subjects will be asked to
      return for an additional visit.
    
  